# Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
Canonical URL: https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-ring-the-nasdaq-closing-bell-on-january-27-2026-to-ce-9dac7952
Ticker: LXRX
Company: Lexicon Pharmaceuticals
Source: Lexicon Pharmaceuticals
Published: 2026-01-23 13:30 EST
## Summary

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq...

## Article Body
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026.

The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain.

“In its early days, Lexicon was focused on pioneering a deeper understanding of the human genome – today, we’ve leveraged that strong scientific foundation to support a compelling pipeline, including late-stage opportunities and commercially available medication,” said Mike Exton, Ph.D., chief executive officer and director of Lexicon. “For 30 years, Lexicon has brought forward medical research and innovation to improve patient lives and drive value for our stakeholders. We’re honored to participate in the Nasdaq closing bell ceremony in celebration of our history, evolution, and continued commitment to patients.”

The Closing Bell ceremony will take place at Nasdaq MarketSite, beginning at 3:45pm ET and will be broadcasted live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony .

About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com .

For Investor and Media Inquiries : Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com
## Recent Company News
- 2026-07-27 12:30 EST — [Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-completes-enrollment-of-pivotal-phase-3-sonata-hcm-study-684930b3) — Source: Lexicon Pharmaceuticals
- 2026-06-03 12:00 EST — [Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions](https://biopharmsignal.com/news/LXRX/lexicon-to-present-data-at-the-american-diabetes-association-ada-2026-scientific-60360dc3) — Source: Lexicon Pharmaceuticals
- 2026-05-28 12:30 EST — [Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-confe-9895b44d) — Source: Lexicon Pharmaceuticals
- 2026-05-12 12:30 EST — [Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-4th-annual-h-c-wainwright-bioconnect-i-e7889bc9) — Source: Lexicon Pharmaceuticals
- 2026-05-07 11:30 EST — [Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provide-4b7317fd) — Source: Lexicon Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)